Case Study:T Cell Transfection by mRNA Lipid Nanoparticles

Since the first FDA approval of chimeric antigen receptor (CAR) T cell therapy in 2017, T cell engineering is continuously the hottest research field in immunotherapy and cell therapy.  Current CAR T cell engineering methods use viral transductions, which induce permanent CAR expression and have potential safety concerns. To overcome these concerns,  researchers are highly interested in non-viral gene deliv-ery methods.  

Recently, CAR mRNA lipid nanoparticles (LNPs) in T cell engineering have been wide-ly studied. The transient transduction feature of mRNA LNP make it a safer profile than viral vectors. The size, homogeneity and mRNA encapsulation efficiency are the key factors for efficient T cell transfection. Using PreciGenome’s NanoGenerator™ system, customer can produce mRNA LNPs with well controlled size, high homogeneity and excellent encapsulation efficiency. 

The following data shows the size and PDI of GFP mRNA lipid nanoparticles synthesized by NanoGenerator™ Flex system.